Advanced glycation end-products (AGEs) may represent a key pathophysiological link and potential therapeutic target in patients with cardiorenal syndrome and diastolic heart failure.
No takes yet. Share an insight, caveat, or question.
AGEs may link cardiorenal syndrome and diastolic HF; hypothesis-generating for targeting, needs prospective trials.
Willemsen et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: